Evaluating the response to antioestrogen toremifene treatment in DMBA induced rat mammary carcinoma.

por Huovinen, R., Kellokumpu-Lehtinen, P. L., Collan, Y.
Publicado em 1994

Baseline psychosocial predictors of survival in localised breast cancer

por Lehto, U-S, Ojanen, M, Dyba, T, Aromaa, A, Kellokumpu-Lehtinen, P
Publicado em 2006

Membranous location of EGFR immunostaining is associated with good prognosis in renal cell carcinoma

por Kallio, J P, Hirvikoski, P, Helin, H, Kellokumpu-Lehtinen, P, Luukkaala, T, Tammela, T L J, Martikainen, P M
Publicado em 2003

Five-year follow-up results of aerobic and impact training on bone mineral density in early breast cancer patients

por Vehmanen, L., Sievänen, H., Kellokumpu-Lehtinen, P., Nikander, R., Huovinen, R., Ruohola, J., Penttinen, H.M., Utriainen, M., Tokola, K., Blomqvist, C., Saarto, T.
Publicado no Osteoporos Int (2020)

Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial

por Joensuu, H., Sailas, L., Alanko, T., Sunela, K., Huuhtanen, R., Utriainen, M., Kokko, R., Bono, P., Wigren, T., Pyrhönen, S., Turpeenniemi-Hujanen, T., Asola, R., Leinonen, M., Hahka-Kemppinen, M., Kellokumpu-Lehtinen, P.
Publicado em 2010

Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial

por Chan, A, Martin, M, Untch, M, Gil, M G, Guillem-Porta, V, Wojtukiewicz, M, Kellokumpu-Lehtinen, P, Sommer, H L, Georgoulias, V, Battelli, N, Pawlicki, M, Aubert, D, Bourlard, T, Gasmi, J, Villanova, G, Petruzelka, L
Publicado em 2006